Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...

Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...

U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

Scientists achieved a genetic breakthrough by removing an extra human chromosome using gene-editing technology. This landmark study successfully deleted the surplus chromosome 21 responsible for Down ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

BEIJING, Dec. 2, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced that its pioneering corn ...

Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...